Clinical trials · New York
Geographic Atrophy clinical trials in New York
We’re tracking 7 recruiting geographic atrophy studies with a site in New York — including Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07606365RecruitingPhase 2
Testing a New Treatment for Geographic Atrophy
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
Hauppauge, New YorkAges 60 years+ - NCT07215390RecruitingPhase 2
Study of APL-3007 plus Syfovre for geographic atrophy
This trial tests whether a new drug called APL-3007, when added to your current Syfovre treatment, can slow the progression of geographic atrophy (an advanced form of dry age-related macular degeneration). It's for people who have already been on Syfovre for at least 6 months.
Great Neck, New YorkAges 60 years+ - NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Brentwood, New YorkAges 50–85 - NCT07441642RecruitingPhase 2
Study of FWY003 for geographic atrophy in age-related macular degeneration
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
New York, New YorkAges 50 years+ - NCT06635148RecruitingPhase 2/Phase 3
Long-term study for geographic atrophy treatment
This study is for people who already took part in a previous trial for geographic atrophy (a late stage of dry age-related macular degeneration) and received the study drug or a sham. It looks at the long-term safety of the treatment over time.
Liverpool, New YorkAges 60 years+ - NCT06659445RecruitingPhase 2
Study of ONL1204 for geographic atrophy in dry AMD
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Liverpool, New YorkAges 55 years+ - NCT05481827Enrolling by invitationPhase 2
Safety follow-up for GT005 in geographic eye damage
This study checks the long-term safety of GT005, a treatment you received in an earlier study, for geographic atrophy related to age-related macular degeneration. It mainly asks you to come to follow-up visits and confirm how you are doing over time.
Rochester, New YorkAges 55 years+
Geographic Atrophy trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting geographic atrophy studies listed above.
- Columbia University Irving Medical Center · 2 studies
- Long Island and Queens Vitreoretinal Consultants of NY, P.C.
- Long Island Vitreoretinal Consultants
- Long Island Vitreoretinal Consultants - Westbury
- Long Island Vitreoretinal Consultants (01050)
- MaculaCare, PLLC
- New York Eye and Ear Infirmary of Mount Sinai
- Northwell Health Manhattan Eye, Ear and Throat Hospital - Ophthalmology
What taking part in a geographic atrophy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Geographic Atrophy trials in other states
Common questions
- Are there geographic atrophy clinical trials in New York?
- Yes. We're currently tracking 7 recruiting geographic atrophy studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a geographic atrophy study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a geographic atrophy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New geographic atrophy studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.